NowPatient vs Walgreens Weight Management
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
NowPatient
Best for early adopters who want Foundayo via a one-stop telehealth platformStarting at $199/mo
Walgreens Weight Management
Best for mainstream telehealth GLP-1 accessSide-by-Side Comparison
| Feature | NowPatient | Walgreens Weight Management |
|---|---|---|
| Overall Score | 7.1/10 | 7.1/10 |
| Starting Price | $199/mo | — |
| Customer Rating | — | — |
| Features | ✓3 features | 2 features |
| States Available | ✓51 | 50 |
| Compounded | — | — |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
NowPatient
Pros
- ✓Confirmed early Foundayo channel (April 2026 rollout)
- ✓Daily oral pill — no needles, no refrigeration
- ✓Telehealth consultation included
Cons
- ✗Pricing tier not yet publicly verified — confirm directly with the provider
- ✗State-by-state availability still being phased in
- ✗Lower mean weight loss vs injectable GLP-1s (~11.1% vs 14.9% Wegovy and 20.9% Zepbound at labeled max)
Walgreens Weight Management
Pros
- ✓Both semaglutide and tirzepatide available
Cons
- ✗Pricing not publicly disclosed
Our Verdict
Both NowPatient and Walgreens Weight Management score equally well overall — the right choice depends on your priorities. Choose NowPatient if you want early adopters who want Foundayo via a one-stop telehealth platform, or Walgreens Weight Management if mainstream telehealth GLP-1 access matters most to you.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.